Markets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Share Price History
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
AstraZeneca Pharma India Ltd.
NSE: ASTRAZEN
|
BSE: 506820
|
ISIN: INE203A01020
|
Industry: Pharmaceuticals
|
Expensive Star
9121.0000
18.50
(
0.20
%)
NSE
Jul 07, 2025
13:25 PM
46.64% Gain from 52W Low
Volume:
10,673
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
AstraZeneca Pharma India Ltd.
edited
01 Dec 2020
9121.00
0.20%
AstraZeneca Sells Former Blockbuster Cholesterol Drug Crestor for $320 Million
NDTV Profit
British drug major sold brand drug to German pharma company Gruenenthal
AstraZeneca Pharma India Ltd. has gained
25.37%
in the last 6 Months
Wockhardt in talks with global vaccine firms for contract manufacturing
Business Standard |
01 Dec 2020
3 more
India Coronavirus Dispatch: How emergency vaccine authorisation works
Business Standard |
01 Dec 2020
AstraZeneca sells cholesterol drug rights to Grnenthal for $320 mln
Economic Times |
01 Dec 2020
AstraZeneca partner sticks with 2 full dose regimen in India Covid trials
Business Standard |
01 Dec 2020
More from AstraZeneca Pharma India Ltd.
Recommended
Market trades flat, IndusInd Bank's net advances decline 3.9% YoY to Rs 3.5 lakh crore in Q1FY26
Trendlyne Marketwatch |
07 Jul 2025, 01:25PM
Five Interesting Stocks Today - July 04, 2025
The Baseline |
04 Jul 2025
Is India getting old before getting rich? | Screener: All star stocks with high five year returns
The Baseline |
03 Jul 2025